Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.

I maintain my Strong Buy rating Lam Research (LRCX) with a revised price target of $455 per share. LRCX’s Q4 2026 results exceeded expectations, supporting an increased FWD non-GAAP EPS estimate to $9 ...

Accurate calibration determines the fidelity of a quantum system; however, a full calibration routine is a time-consuming ...

Major stock indexes pulled back sharply ahead of the Federal Reserve’s decision on interest rates and Big Tech earnings ...

Learn their language, but please don't attempt to use it ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that updated clinical results from the Phase 1b TheraPb trial ...

The Austin-based drone boat company helping Texas lead the U.S. war against Iran is now building what is expected to be the largest shipyard in the ...

Oversubscribed financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from new investors Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price, a ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the closing of an oversubscribed and upsized US $315 million Series D ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the closing of an oversubscribed and upsized US $315 million Series D ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Ajay Devgn's Dhamaal 4, directed by Indra Kumar, is expected to take a decent start in the vicinity of Rs. 12 crore to Rs. 14 crore nett at the Indian box office.